# Rock Springs Capital Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1595725. Source: https://holderbook.com/funds/1595725-rock-springs-capital-management-lp/

- Reported value: $2.0B
- Positions: 104
- Weight of the ten largest: 44.0%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $207.0M | 1,105,210 | 10.1% | 14 |
| TRAVERE THERAPEUTICS INC | [TVTX](https://holderbook.com/stocks/TVTX/) | $123.8M | 2,179,069 | 6.0% | 23 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $118.4M | 98,700 | 5.8% | 11 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $94.0M | 174,999 | 4.6% | 31 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $93.4M | 798,145 | 4.6% | 28 |
| RHYTHM PHARMACEUTICALS INC | [RYTM](https://holderbook.com/stocks/RYTM/) | $76.9M | 692,598 | 3.8% | 31 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $52.0M | 453,156 | 2.5% | 24 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $48.9M | 52,750 | 2.4% | 31 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $45.0M | 168,750 | 2.2% | 1 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $41.3M | 683,907 | 2.0% | 26 |
| SCHOLAR ROCK HLDG CORP | [SRRK](https://holderbook.com/stocks/SRRK/) | $39.3M | 715,452 | 1.9% | 7 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $38.6M | 362,150 | 1.9% | 9 |
| PENUMBRA INC | [PEN](https://holderbook.com/stocks/PEN/) | $36.5M | 115,750 | 1.8% | 31 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $34.4M | 640,317 | 1.7% | 11 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $32.3M | 967,855 | 1.6% | 31 |
| IRHYTHM HOLDINGS INC | [IRTC](https://holderbook.com/stocks/IRTC/) | $32.1M | 269,650 | 1.6% | 31 |
| INTUITIVE SURGICAL INC | [ISRG](https://holderbook.com/stocks/ISRG/) | $30.4M | 76,460 | 1.5% | 31 |
| AGILON HEALTH INC | [AGL](https://holderbook.com/stocks/AGL/) | $28.1M | 262,600 | 1.4% | 2 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $26.5M | 63,750 | 1.3% | 3 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $26.0M | 699,146 | 1.3% | 18 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $25.7M | 1,402,150 | 1.3% | 3 |
| NEUROCRINE BIOSCIENCES INC | [NBIX](https://holderbook.com/stocks/NBIX/) | $24.4M | 144,750 | 1.2% | 31 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $23.6M | 464,625 | 1.2% | 10 |
| TENET HEALTHCARE CORP | [THC](https://holderbook.com/stocks/THC/) | $23.4M | 125,000 | 1.1% | 7 |
| DEXCOM INC | [DXCM](https://holderbook.com/stocks/DXCM/) | $23.1M | 343,000 | 1.1% | 22 |
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $22.9M | 4,330,532 | 1.1% | 31 |
| MINIMED GROUP INC | [MMED](https://holderbook.com/stocks/MMED/) | $22.7M | 1,520,000 | 1.1% | 2 |
| BOSTON SCIENTIFIC CORP | [BSX](https://holderbook.com/stocks/BSX/) | $22.6M | 528,500 | 1.1% | 13 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $22.4M | 648,333 | 1.1% | 10 |
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $21.8M | 662,918 | 1.1% | 1 |
| HEMAB THERAPEUTICS HLDGS INC | - | $21.1M | 575,432 | 1.0% | 1 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $20.9M | 942,154 | 1.0% | 10 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $20.1M | 66,750 | 1.0% | 31 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $20.0M | 515,917 | 1.0% | 5 |
| AGIOS PHARMACEUTICALS INC | [AGIO](https://holderbook.com/stocks/AGIO/) | $19.8M | 532,563 | 1.0% | 30 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMS](https://holderbook.com/stocks/NAMS/) | $19.7M | 582,744 | 1.0% | 8 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $18.3M | 427,584 | 0.9% | 10 |
| TARSUS PHARMACEUTICALS INC | [TARS](https://holderbook.com/stocks/TARS/) | $17.4M | 277,087 | 0.9% | 7 |
| HEARTFLOW INC | [HTFL](https://holderbook.com/stocks/HTFL/) | $16.8M | 573,500 | 0.8% | 4 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $16.5M | 298,218 | 0.8% | 4 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $16.0M | 187,980 | 0.8% | 3 |
| BICARA THERAPEUTICS INC | [BCAX](https://holderbook.com/stocks/BCAX/) | $15.9M | 535,286 | 0.8% | 8 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $15.8M | 578,028 | 0.8% | 1 |
| ZAI LAB LTD | [ZLAB](https://holderbook.com/stocks/ZLAB/) | $15.5M | 814,707 | 0.8% | 31 |
| DANAHER CORP DEL | [DHR](https://holderbook.com/stocks/DHR/) | $14.5M | 76,300 | 0.7% | 6 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $14.3M | 456,551 | 0.7% | 3 |
| EVOLENT HEALTH INC | [EVH](https://holderbook.com/stocks/EVH/) | $13.6M | 2,500,000 | 0.7% | 22 |
| PTC THERAPEUTICS INC | [PTCT](https://holderbook.com/stocks/PTCT/) | $13.2M | 162,298 | 0.6% | 3 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $13.1M | 484,951 | 0.6% | 6 |
| ZENAS BIOPHARMA INC | [ZBIO](https://holderbook.com/stocks/ZBIO/) | $12.7M | 502,077 | 0.6% | 8 |
| ARDELYX INC | [ARDX](https://holderbook.com/stocks/ARDX/) | $11.4M | 2,241,769 | 0.6% | 7 |
| INSPIRE MED SYS INC | [INSP](https://holderbook.com/stocks/INSP/) | $10.9M | 244,000 | 0.5% | 12 |
| BRIDGEBIO PHARMA INC | [BBIO](https://holderbook.com/stocks/BBIO/) | $10.8M | 144,750 | 0.5% | 4 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $10.5M | 199,811 | 0.5% | 4 |
| SUMMIT THERAPEUTICS INC | [SMMT](https://holderbook.com/stocks/SMMT/) | $10.4M | 715,000 | 0.5% | 8 |
| AZENTA INC | [AZTA](https://holderbook.com/stocks/AZTA/) | $10.3M | 403,000 | 0.5% | 17 |
| INDIVIOR PHARMACEUTICALS INC | [INDV](https://holderbook.com/stocks/INDV/) | $10.1M | 245,500 | 0.5% | 2 |
| STRYKER CORPORATION | [SYK](https://holderbook.com/stocks/SYK/) | $9.1M | 29,000 | 0.4% | 2 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $9.0M | 499,764 | 0.4% | 6 |
| CARIS LIFE SCIENCES INC | [CAI](https://holderbook.com/stocks/CAI/) | $8.7M | 487,500 | 0.4% | 5 |
| OMADA HEALTH INC | [OMDA](https://holderbook.com/stocks/OMDA/) | $8.2M | 373,000 | 0.4% | 5 |
| COMPASS THERAPEUTICS INC | [CMPX](https://holderbook.com/stocks/CMPX/) | $7.7M | 3,524,929 | 0.4% | 19 |
| IMMUNOME INC | [IMNM](https://holderbook.com/stocks/IMNM/) | $7.4M | 347,666 | 0.4% | 3 |
| EDAP TMS S A | [FOCL](https://holderbook.com/stocks/FOCL/) | $7.2M | 1,386,000 | 0.4% | 21 |
| PHREESIA INC | [PHR](https://holderbook.com/stocks/PHR/) | $7.2M | 696,900 | 0.4% | 28 |
| OMEROS CORP | [OMER](https://holderbook.com/stocks/OMER/) | $6.8M | 718,499 | 0.3% | 1 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $6.7M | 143,187 | 0.3% | 1 |
| CORCEPT THERAPEUTICS INC | [CORT](https://holderbook.com/stocks/CORT/) | $6.3M | 72,000 | 0.3% | 3 |
| JANUX THERAPEUTICS INC | [JANX](https://holderbook.com/stocks/JANX/) | $5.6M | 367,009 | 0.3% | 7 |
| MOBIA MED INC | - | $5.6M | 418,200 | 0.3% | 1 |
| ARCUS BIOSCIENCES INC | [RCUS](https://holderbook.com/stocks/RCUS/) | $5.5M | 180,000 | 0.3% | 3 |
| THERMO FISHER SCIENTIFIC INC | [TMO](https://holderbook.com/stocks/TMO/) | $5.0M | 10,000 | 0.2% | 5 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $4.8M | 260,000 | 0.2% | 1 |
| SIONNA THERAPEUTICS INC | [SION](https://holderbook.com/stocks/SION/) | $4.4M | 99,429 | 0.2% | 6 |
| CVS HEALTH CORP | [CVS](https://holderbook.com/stocks/CVS/) | $4.1M | 40,000 | 0.2% | 2 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $3.8M | 268,519 | 0.2% | 4 |
| OCULAR THERAPEUTIX INC | [OCUL](https://holderbook.com/stocks/OCUL/) | $3.8M | 383,716 | 0.2% | 4 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $3.8M | 42,254 | 0.2% | 1 |
| TALPHERA INC | [TLPH](https://holderbook.com/stocks/TLPH/) | $3.7M | 3,589,186 | 0.2% | 15 |
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $3.6M | 101,000 | 0.2% | 3 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $3.5M | 60,250 | 0.2% | 5 |
| NEUROGENE INC | [NGNE](https://holderbook.com/stocks/NGNE/) | $3.4M | 106,750 | 0.2% | 7 |
| CENTURY THERAPEUTICS INC | [IPSC](https://holderbook.com/stocks/IPSC/) | $3.2M | 1,304,347 | 0.2% | 2 |
| ALPHATEC HLDGS INC | [ATEC](https://holderbook.com/stocks/ATEC/) | $3.1M | 360,000 | 0.2% | 7 |
| NOVO-NORDISK A S | [NVO](https://holderbook.com/stocks/NVO/) | $3.0M | 63,500 | 0.1% | 2 |
| OLEMA PHARMACEUTICALS INC | [OLMA](https://holderbook.com/stocks/OLMA/) | $2.9M | 235,178 | 0.1% | 3 |
| NERVGEN PHARMA CORP | [NGEN](https://holderbook.com/stocks/NGEN/) | $2.5M | 1,208,231 | 0.1% | 1 |
| MEDTRONIC PLC | [MDT](https://holderbook.com/stocks/MDT/) | $2.4M | 30,900 | 0.1% | 1 |
| TEVA PHARMACEUTICAL INDS LTD | [TEVA](https://holderbook.com/stocks/TEVA/) | $2.0M | 59,000 | 0.1% | 3 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $2.0M | 20,326 | 0.1% | 2 |
| SAGIMET BIOSCIENCES INC | [SGMT](https://holderbook.com/stocks/SGMT/) | $1.9M | 250,000 | 0.1% | 1 |
| CAPRICOR THERAPEUTICS INC | [CAPR](https://holderbook.com/stocks/CAPR/) | $1.8M | 74,448 | 0.1% | 1 |
| LENZ THERAPEUTICS INC | [LENZ](https://holderbook.com/stocks/LENZ/) | $1.5M | 257,460 | 0.1% | 7 |
| ALTIMMUNE INC | [ALT](https://holderbook.com/stocks/ALT/) | $1.4M | 471,465 | 0.1% | 1 |
| KAILERA THERAPEUTICS INC | [KLRA](https://holderbook.com/stocks/KLRA/) | $1.4M | 65,000 | 0.1% | 1 |
| SURGERY PARTNERS INC | [SGRY](https://holderbook.com/stocks/SGRY/) | $1.4M | 84,000 | 0.1% | 3 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $1.3M | 5,500 | 0.1% | 1 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $1.1M | 12,051 | 0.1% | 2 |
| VIKING THERAPEUTICS INC | [VKTX](https://holderbook.com/stocks/VKTX/) | $994.8K | 25,500 | 0.0% | 2 |
| LEGEND BIOTECH CORP | [LEGN](https://holderbook.com/stocks/LEGN/) | $967.5K | 33,500 | 0.0% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +22.3% | +14.8% | +7.5% | 97% |
| Q1 2026 | -4.8% | -4.6% | -0.2% | 96% |
| Q4 2025 | +18.5% | +2.4% | +16.2% | 98% |
| Q3 2025 | +20.5% | +7.8% | +12.7% | 100% |
| Q2 2025 | +6.6% | +10.5% | -3.9% | 99% |
| Q1 2025 | -7.8% | -4.6% | -3.2% | 100% |
| Q4 2024 | -6.3% | +2.1% | -8.5% | 100% |
| Q3 2024 | +4.4% | +5.4% | -1.1% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $2.0B | 104 |
| Q1 2026 | $1.7B | 100 |
| Q4 2025 | $2.0B | 98 |
| Q3 2025 | $1.7B | 92 |
| Q2 2025 | $1.6B | 93 |
| Q1 2025 | $1.7B | 96 |
| Q4 2024 | $2.6B | 107 |
| Q3 2024 | $3.1B | 109 |
| Q2 2024 | $3.3B | 110 |
| Q1 2024 | $3.9B | 113 |
| Q4 2023 | $4.1B | 104 |
| Q3 2023 | $3.7B | 120 |